Innovative Pharmaceutical Biotech (0399) Price & Analysis

Q: What was Innovative Pharmaceutical Biotech Limited’s price range in the past 12 months?

Innovative Pharmaceutical Biotech Limited lowest stock price was HK$0.06 and its highest was HK$0.73 in the past 12 months.

Q: What is Innovative Pharmaceutical Biotech Limited’s market cap?

Innovative Pharmaceutical Biotech Limited’s market cap is HK$212.14M.

Q: When is Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date?

Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date is Jun 25, 2026 which is in 188 days.

Q: How were Innovative Pharmaceutical Biotech Limited’s earnings last quarter?

Innovative Pharmaceutical Biotech Limited released its earnings results on Nov 28, 2025. The company reported -HK$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.06.

Q: Is Innovative Pharmaceutical Biotech Limited overvalued?

According to Wall Street analysts Innovative Pharmaceutical Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Innovative Pharmaceutical Biotech Limited pay dividends?

Innovative Pharmaceutical Biotech Limited does not currently pay dividends.

Q: What is Innovative Pharmaceutical Biotech Limited’s EPS estimate?

Innovative Pharmaceutical Biotech Limited’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Innovative Pharmaceutical Biotech Limited have?

Innovative Pharmaceutical Biotech Limited has 2,142,787,600 shares outstanding.

Q: What happened to Innovative Pharmaceutical Biotech Limited’s price movement after its last earnings report?

Innovative Pharmaceutical Biotech Limited reported an EPS of -HK$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.5%.

Q: Which hedge fund is a major shareholder of Innovative Pharmaceutical Biotech Limited?

Currently, no hedge funds are holding shares in HK:0399

Compare

0 Followers

0399 Stock Chart & Stats

HK$0.10

>-HK$0.01(-3.77%)

At close: Jan 09 4:00 PM EST

HK$0.10

>-HK$0.01(-3.77%)

Day’s Range― - ―

52-Week RangeHK$0.06 - HK$0.73

Previous CloseN/A

Volume1.53M

Average Volume (3M)17.09M

Market Cap

HK$212.14M

Enterprise ValueHK$2.47B

Total Cash (Recent Filing)HK$3.70M

Total Debt (Recent Filing)HK$1.00B

Price to Earnings (P/E)14.9

Beta0.63

Next Earnings

Jun 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding2,142,787,600

10 Day Avg. Volume17,323,689

30 Day Avg. Volume17,085,593

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.44

Price to Sales (P/S)143.85

P/FCF Ratio-28.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Innovative Pharmaceutical Biotech News

Starcoin Deepens Johns Hopkins Ties in Five-Year Diabetes Research Pact

Innovative Pharmaceutical Biotech ( ($HK:0399) ) has shared an announcement. Starcoin Group Limited has signed a five-year Sponsored...

17h ago

0399

Starcoin Group Announces Amendment to Convertible Bonds

An update from Innovative Pharmaceutical Biotech ( ($HK:0399) ) is now available. Starcoin Group Limited has announced a...

17d ago

0399

Starcoin Group Reports Significant Interim Loss Amid Rising Costs

Innovative Pharmaceutical Biotech ( ($HK:0399) ) has shared an announcement. Starcoin Group Limited announced its unaudited interim results...

21d ago

0399

Starcoin Group Seeks Review of Stock Exchange Suspension Decision

Innovative Pharmaceutical Biotech ( ($HK:0399) ) has provided an update. Starcoin Group Limited has requested a review of...

25d ago

0399

Starcoin Group Limited Announces Upcoming Board Meeting for Interim Results

The latest announcement is out from Innovative Pharmaceutical Biotech ( ($HK:0399) ). Starcoin Group Limited has announced a...

30d ago

0399

Starcoin Group Faces Potential Trading Suspension on Hong Kong Stock Exchange

An announcement from Innovative Pharmaceutical Biotech ( ($HK:0399) ) is now available. Starcoin Group Limited has been notified...

1M ago

0399

Starcoin Group Limited Updates on Token Issue Plans

Innovative Pharmaceutical Biotech ( ($HK:0399) ) has provided an announcement. Starcoin Group Limited announced a supplemental update regarding...

2M ago

0399

Starcoin Group Extends Long Stop Dates for Share Subscription Agreements

Innovative Pharmaceutical Biotech ( ($HK:0399) ) has issued an update. Starcoin Group Limited has announced a further extension...

2M ago

0399

Starcoin Group Limited Denies Merger Rumors and Warns Investors

Innovative Pharmaceutical Biotech ( ($HK:0399) ) just unveiled an update. Starcoin Group Limited has issued a clarification regarding...

2M ago

0399

Starcoin Group Limited Announces Strategic MOUs in Blockchain and Biotechnology

An announcement from Innovative Pharmaceutical Biotech ( ($HK:0399) ) is now available. Starcoin Group Limited has entered into...

2M ago

0399

0399 FAQ

What was Innovative Pharmaceutical Biotech Limited’s price range in the past 12 months?

Innovative Pharmaceutical Biotech Limited lowest stock price was HK$0.06 and its highest was HK$0.73 in the past 12 months.

What is Innovative Pharmaceutical Biotech Limited’s market cap?

Innovative Pharmaceutical Biotech Limited’s market cap is HK$212.14M.

When is Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date?

Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date is Jun 25, 2026 which is in 188 days.

How were Innovative Pharmaceutical Biotech Limited’s earnings last quarter?

Innovative Pharmaceutical Biotech Limited released its earnings results on Nov 28, 2025. The company reported -HK$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.06.

Is Innovative Pharmaceutical Biotech Limited overvalued?

According to Wall Street analysts Innovative Pharmaceutical Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Innovative Pharmaceutical Biotech Limited pay dividends?

Innovative Pharmaceutical Biotech Limited does not currently pay dividends.

What is Innovative Pharmaceutical Biotech Limited’s EPS estimate?

Innovative Pharmaceutical Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Innovative Pharmaceutical Biotech Limited have?

Innovative Pharmaceutical Biotech Limited has 2,142,787,600 shares outstanding.

What happened to Innovative Pharmaceutical Biotech Limited’s price movement after its last earnings report?

Innovative Pharmaceutical Biotech Limited reported an EPS of -HK$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.5%.

Which hedge fund is a major shareholder of Innovative Pharmaceutical Biotech Limited?

Currently, no hedge funds are holding shares in HK:0399

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Innovative Pharmaceutical Biotech Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-0.24%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Innovative Pharmaceutical Biotech Limited

Innovative Pharmaceutical Biotech (0399) is a biotechnology company operating in the pharmaceutical sector. The company is focused on the discovery, development, and commercialization of novel therapeutic products. Its core products are centered around cutting-edge treatments and biotechnological innovations aimed at addressing unmet medical needs across various therapeutic areas.